Back to mobile site

Goldman Sachs: 'we expect GILD to continue to engage in strategic BD'

March 24, 2026 6:36 AM EDT Send to a Friend
Goldman Sachs analyst Salveen Richter reiterated a Neutral rating and $125.00 price target on Gilead Sciences (NASDAQ: GILD).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login